🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07054593
Starting soon Phase 1

Effect of Proton Pump Inhibitors on Gut Microbiota Composition and Metabolites in Healthy Subjects Using CapScan

NCT07054593 · tracked via the Priya Life Science USA tracker
Sponsor
Envivo Bio Inc
Phase
Phase 1
Started
2025-12-01
Last updated
2025-07-08

Condition(s) studied

Healthy Subjects

Investigational drug(s) / intervention(s)

CapScan

CapScan: Gut sampling capsule

Study summary

This study is designed to evaluate the effect of proton pump inhibitors on the regional composition of the gut microbiota and metabolic profiles of health volunteers using the CapScan collection capsule.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
INCLUSION CRITERIA Subjects must meet all of the following criteria to be included in the study: * Males or females 18 years of age or older and 85 years of age or younger at the time of the first Screening Visit. * ASA Classification 1 or 2. * For women of childbearing potential, negative urine pregnancy test within 7 days of Screening Visit. Willingness to use highly effective contraception during the entire study period (e.g.: implants, injectables, oral contraceptives, intra-uterine device or declared abstinence). * Subject is fluent in English and understands the study protocol and informed consent and is willing and able to comply with study requirements and sign the informed consent form. EXCLUSION CRITERIA Subjects with any of the following conditions or characteristics must be excluded from the study: * History of any of the following: * prior gastric or esophageal surgery, including bariatric surgery * bowel obstruction * gastric outlet obstruction * gastroparesis * acute diverticulitis * inflammatory bowel disease * ileostomy or colostomy * gastric or esophageal cancer * achalasia * active dysphagia or odynophagia * Daily PPI use in the last 30 days * Pregnancy or planned pregnancy within 30 days from Screening Visit, or breast-feeding * Any form of active substance abuse or dependence (including drug or alcohol abuse), unstable medical or psychiatric disorder, or any chronic condition susceptible, in the opinion of the investigator, to interfere with the conduct of the study * A clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the subject while involved in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Silicon Valley Gastroenterology Mountain View California

More Envivo Bio Inc trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07054593 on ClinicalTrials.gov ↗ ← All trials in the USA